Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Undergraduate Student Research Awards (USRA)

University of Toronto

$6,000.00

EPC therapy for fracture healing

EF 2023-24

Résumé
Our musculoskeletal lab has been investigating the role of endothelial progenitor cells (EPCs) as a potential therapy for non-healing fractures. Work with EPCs and their local delivery to a small animal model of nonunion has shown significant promise for the management of nonunions. As a next step in the process of translating this work to the clinical realm, we plan to investigate the role of human EPCs in an immunodeficient animal model of nonunion. Beyond validating the effectiveness of human EPCs in fracture healing, this study will also assess the effect of diabetes on the biological activity of human EPCs. We will obtain EPCs from i) healthy volunteers ii) those with early type II diabetes and iii) those with advanced type II diabetes. EPCs will be obtained using peripheral apheresis and isolated using established methods. 32 RNU immunodeficient rats will be randomly divided into 4 groups; i) control ii) EPC treatment from healthy patients iii) EPC treatment [early diabetes] iv) EPC treatment [advanced diabetes]. A 5mm defect will be created in the right femora, stabilized with a miniplate and screws, and the defect will be filled with EPCs or control as per the animal's randomization. Outcomes of bone defect healing will be radiographic appearance, morphologic characteristics on microCT and biomechanical properties at the 10 week mark. This study will allow us to elucidate the viability of human EPCs in fracture healing in a pre-clinical model, while also examining the effect of a common comorbidity on their relative potency for this purpose. Thus, this work will be an important step towards clinical translation of this therapy, with the potential to significantly improve outcomes for patients with non-healing fractures.
Programme
Undergraduate Student Research Awards (USRA)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486938
Name
Hassan Omar
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
EPC therapy for fracture healing
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Toronto
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Animal; Biomedical; Cells; Comorbidity; Fractures; Human; Immunodeficient; Musculoskeletal; Patients; Progenitor; Therapy
Abstract
Our musculoskeletal lab has been investigating the role of endothelial progenitor cells (EPCs) as a potential therapy for non-healing fractures. Work with EPCs and their local delivery to a small animal model of nonunion has shown significant promise for the management of nonunions. As a next step in the process of translating this work to the clinical realm, we plan to investigate the role of human EPCs in an immunodeficient animal model of nonunion. Beyond validating the effectiveness of human EPCs in fracture healing, this study will also assess the effect of diabetes on the biological activity of human EPCs. We will obtain EPCs from i) healthy volunteers ii) those with early type II diabetes and iii) those with advanced type II diabetes. EPCs will be obtained using peripheral apheresis and isolated using established methods. 32 RNU immunodeficient rats will be randomly divided into 4 groups; i) control ii) EPC treatment from healthy patients iii) EPC treatment [early diabetes] iv) EPC treatment [advanced diabetes]. A 5mm defect will be created in the right femora, stabilized with a miniplate and screws, and the defect will be filled with EPCs or control as per the animal's randomization. Outcomes of bone defect healing will be radiographic appearance, morphologic characteristics on microCT and biomechanical properties at the 10 week mark. This study will allow us to elucidate the viability of human EPCs in fracture healing in a pre-clinical model, while also examining the effect of a common comorbidity on their relative potency for this purpose. Thus, this work will be an important step towards clinical translation of this therapy, with the potential to significantly improve outcomes for patients with non-healing fractures.
Competitiondate
202305
Approvedterm2
0 yr 4 mths
Pinamesdelim
Hassan, Omar
Approvedterm
0 an 4 mois
Cihrcontribution2
~ $6,000~ $0~